(Q48339651)

English

Open-label administration of lisdexamfetamine dimesylate improves executive function impairments and symptoms of attention-deficit/hyperactivity disorder in adults

scientific article published in September 2010

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/20861583

Open-label administration of lisdexamfetamine dimesylate improves executive function impairments and symptoms of attention-deficit/hyperactivity disorder in adults (English)

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/20861583

1 reference

based on heuristic

inferred from title

attention deficit hyperactivity disorder

1 reference

based on heuristic

inferred from title

Ann C. Childress

5

object named as

Ann Childress

0 references

2

object named as

Matthew Brams

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/20861583

author name string

Thomas E Brown

1

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/20861583

Joseph Gao

3

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/20861583

Maria Gasior

4

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/20861583

language of work or name

0 references

publication date

1 September 2010

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/20861583

Postgraduate Medicine

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/20861583

122

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/20861583

5

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/20861583

7-17

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/20861583

The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.09.2196

21 January 2018

Characterizing cognition in ADHD: beyond executive dysfunction

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.09.2196

21 January 2018

Behavioral inhibition, sustained attention, and executive functions: constructing a unifying theory of ADHD

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.09.2196

21 January 2018

Validity of the executive function theory of attention-deficit/hyperactivity disorder: a meta-analytic review

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.09.2196

21 January 2018

Impact of psychometrically defined deficits of executive functioning in adults with attention deficit hyperactivity disorder

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.09.2196

21 January 2018

Neuropsychology of adults with attention-deficit/hyperactivity disorder: a meta-analytic review

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.09.2196

21 January 2018

Causal Heterogeneity in Attention-Deficit/Hyperactivity Disorder: Do We Need Neuropsychologically Impaired Subtypes?

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.09.2196

21 January 2018

Executive function impairments in high IQ adults with ADHD.

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.09.2196

21 January 2018

Deficits in strategy application following frontal lobe damage in man.

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.09.2196

21 January 2018

ADHD outside the laboratory: boys' executive function performance on tasks in videogame play and on a visit to the zoo.

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.09.2196

21 January 2018

Reliability, validity, and utility of instruments for self-report and informant report concerning symptoms of ADHD in adult patients.

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.09.2196

21 January 2018

NICE guideline: attention deficit hyperactivity disorder

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.09.2196

21 January 2018

Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: novel findings using a simulated adult workplace environment design

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.09.2196

21 January 2018

Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.09.2196

21 January 2018

A 13-hour laboratory school study of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.09.2196

21 January 2018

Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR)

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.09.2196

21 January 2018

Remission versus response as the goal of therapy in ADHD: a new standard for the field?

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.09.2196

21 January 2018

Clinical relevance of the primary findings of the MTA: success rates based on severity of ADHD and ODD symptoms at the end of treatment

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.09.2196

21 January 2018

A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.09.2196

21 January 2018

A randomized, placebo-controlled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.09.2196

21 January 2018

Efficacy and safety of dexmethylphenidate extended-release capsules in adults with attention-deficit/hyperactivity disorder.

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.09.2196

21 January 2018

Does OROS-methylphenidate improve core symptoms and deficits in executive function? Results of an open-label trial in adults with attention deficit hyperactivity disorder

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.09.2196

21 January 2018

Methylphenidate improves aspects of executive function in African American children with ADHD.

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.09.2196

21 January 2018

Executive function and attention deficit hyperactivity disorder: stimulant medication and better executive function performance in children.

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.09.2196

21 January 2018

Effectiveness, safety, and tolerability of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: an open-label, dose-optimization study

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.09.2196

21 January 2018

Executive functions and adaptive functioning in young adult attention-deficit/hyperactivity disorder.

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.09.2196

21 January 2018

Identifiers

10.3810/PGM.2010.09.2196

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/20861583

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/20861583

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48339651&oldid=2195559992"